Patient Care Editorial Staff

Patient Care tapped the rich trove of research and expert perspective from the 2025 Revolutionizing Atopic Dermatitis meeting to create a snapshot of the AD care of the future.

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

The US FDA approved Tonmya, a groundbreaking treatment for fibromyalgia, offering hope to millions experiencing chronic pain and sleep issues.

Primary care clinicians are generally the first clinical contact for older adults with early signs of dementia. Our survey uncovered 5 primary challenges to being in that role.

New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.

Every patient should be offered evidence-based analgesia for pain management for in-office uterine and cervical procedures after shared, trauma-informed decision-making.

A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.

Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

Two posters at AAD 2025 highlighted different challenges of managing patients with HS.

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.

Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.

The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.